Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 12:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 5,455 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Solid Malignancy Clear all
Recruiting Phase 1Phase 2 Interventional

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

NCT07287917
View directory record Official record
Conditions
Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
Interventions
AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
20
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 12:22 AM EDT
Active, not recruiting Phase 1 Interventional

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

NCT05462717
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
Interventions
RMC-6291
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Springdale, Arkansas • Orange, California • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 23, 2026, 12:22 AM EDT
Completed Phase 1 Interventional

Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide

NCT00006047
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Oral Etoposide, Oral 9-Nitrocamptothecin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Oct 23, 2026, 12:22 AM EDT
Recruiting Phase 3 Interventional

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

NCT07410117
View directory record Official record
Conditions
Cancer-Associated Thrombosis (CAT)
Interventions
REGN7508, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Hialeah, Florida • North Miami Beach, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 12:22 AM EDT
Recruiting No phase listed Observational

Immune Profiling for Cancer Immunotherapy Response

NCT06116032
View directory record Official record
Conditions
Cancer, Tumor, Solid, Hematologic Malignancy, Blood Cancer
Interventions
Methylation Cytometry
Diagnostic Test
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 23, 2026, 12:22 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study of S-3304 in Patients With Solid Tumors

NCT00033215
View directory record Official record
Conditions
Solid Tumors
Interventions
S-3304
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
4
States / cities
Denver, Colorado • Tampa, Florida • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 23, 2026, 12:22 AM EDT
Withdrawn Phase 1 Interventional

A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors

NCT00682279
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
oral topotecan (SK&F-104864); lapatinib (GW572016)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 23, 2026, 12:22 AM EDT
Withdrawn Phase 2 Interventional

Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore)

NCT02766842
View directory record Official record
Conditions
Mesenchymal Tumor, Autoimmune Pancreatitis, Lymphoma, Solid Tumors
Interventions
EUS-FNB with ProCore needle, EUS-FNB with SharkCore needle, ProCore needle, SharkCore needle
Procedure · Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 23, 2026, 12:22 AM EDT
Completed Phase 2 Interventional

High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors

NCT00003173
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Ovarian Cancer, Retinoblastoma, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 23, 2026, 12:22 AM EDT
Completed Phase 1 Interventional

Octreotide and Doxorubicin in Treating Patients With Advanced Cancer

NCT00008073
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
doxorubicin hydrochloride, octreotide acetate
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 23, 2026, 12:22 AM EDT
Completed Phase 1 Interventional

A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available

NCT00785941
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
IMC-A12
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2011 · Synced Oct 23, 2026, 12:22 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

NCT04439331
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Defactinib Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 23, 2026, 12:22 AM EDT
Terminated Phase 1 Interventional

A Trial of ALB 109564(a) in Subjects With Advanced Solid Tumors

NCT00724100
View directory record Official record
Conditions
Cancer
Interventions
ALB 109564(a) (12´-methylthiovinblastine dihydrochloride)
Drug
Lead sponsor
Albany Molecular Research, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2014 · Synced Oct 23, 2026, 12:22 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors

NCT04447222
View directory record Official record
Conditions
COVID-19 Infection, Malignant Solid Neoplasm
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
1,242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 12:22 AM EDT
Terminated Phase 1 Interventional

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

NCT04261439
View directory record Official record
Conditions
In Escalation: All Patients With Solid Tumors and Lymphoma, In Expansion: Melanoma, Non-small Cell Lung Cancer
Interventions
NIZ985, Spartalizumab, Tislelizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Duarte, California • La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 23, 2026, 12:22 AM EDT
Completed Phase 1 Interventional

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

NCT02219711
View directory record Official record
Conditions
Advanced Cancer
Interventions
MGCD516
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
37
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 23, 2026, 12:22 AM EDT
Completed Phase 1 Interventional

Phase I Study of TAS-106 in Combo With Carboplatin

NCT00752011
View directory record Official record
Conditions
Cancer, Solid Tumors
Interventions
TAS-106, Carboplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2012 · Synced Oct 23, 2026, 12:22 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

NCT02586987
View directory record Official record
Conditions
Lung Cancer, Melanoma, Head and Neck Carcinoma, Gastroesophageal Cancer, Breast Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Biliary Tract Cancer
Interventions
Selumetinib, MEDI4736, Tremelimumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 23, 2026, 12:22 AM EDT
Completed Phase 1 Interventional

This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor

NCT00033202
View directory record Official record
Conditions
Solid Malignancies
Interventions
Gimatecan® (ST-1481)
Drug
Lead sponsor
Sigma-Tau Research, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
3
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Oct 23, 2026, 12:22 AM EDT
Completed Phase 1 Interventional

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03071757
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
ABBV-368, ABBV-181
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
La Jolla, California • Sacramento, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 23, 2026, 12:22 AM EDT
Completed Phase 3 Interventional

Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer

NCT00020657
View directory record Official record
Conditions
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
dolasetron mesylate, granisetron hydrochloride, ondansetron, prochlorperazine, quality-of-life assessment
Drug · Procedure
Lead sponsor
Gary Morrow
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 23, 2026, 12:22 AM EDT
Completed Phase 1 Interventional

Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies

NCT00629200
View directory record Official record
Conditions
Advanced Cancer, Solid Tumors
Interventions
Sodium Stibogluconate, Interferon Alpha-2b
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Albuquerque, New Mexico • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 23, 2026, 12:22 AM EDT
Completed Phase 1 Interventional

Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

NCT02680795
View directory record Official record
Conditions
Solid Tumors, Hematological Malignancies
Interventions
Belinostat IV
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Santa Monica, California • Whittier, California • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 23, 2026, 12:22 AM EDT
Completed No phase listed Observational

Evaluating Clinical Evaluation Tools for Predicting Risk of Complications After Hematopoietic Stem Cell Transplant

NCT05766332
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions
Clinical Evaluation, Electronic Health Record Review
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 23, 2026, 12:22 AM EDT